07:21 EDT Viking Therapeutics (VKTX) falls 29% to $29.60 after Phase 2 VK2735 test results
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics’ VK2735 achieves endpoints in Phase 2 obesity trial
- Viking Therapeutics’ VK2735: A Promising Contender in the Obesity Treatment Market
- Viking Therapeutics call volume above normal and directionally bullish
- BofA defends Eli Lilly following selloff on weight loss pill trial data
- Promising Phase 1 Results for Viking Therapeutics’ VK2735 Justify Buy Rating